NEW YORK, Nov. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People's Republic of China, in 2012 cardiovascular disease deaths in China reached 3.5 million. The fast growing number of heart patients stimulated rapid growth in Chinese demand for interventional cardiac operation and coronary stent. China's PCI (percutaneous coronary intervention) surgeries increased from 25,000 cases in 2002 to about 531,000 cases in 2012; the number of coronary stent implantation rose from 40,000 units in 2002 to approximately 640,000 units in 2012. In 2007-2012 China's cardiovascular stent market size grew at an AAGR of 20.3%.
In China, interventional cardiovascular devices are dominated by cardiovascular stent. Currently, the top three companies in China's coronary stent market are respectively MicroPort, Lepu Medical and JW Medical; while supporting auxiliary devices such as catheter and guide wire feature low localization rate, mainly dependent on imports. In 2012, Chinese enterprises accounted for 66.8% of Chinese interventional cardiovascular device market share, followed by foreign counterparts with 33.2%.
Interventional cardiovascular device is a sunrise industry, there lies strong clinical demand for safer and more effective interventional products, and thus the world's major manufacturers have invested heavily in research and development of new products. Bioabsorbable everolimus-eluting stent (BVS) has become the focus of attention. Abbott in September 2012 launched the world's first A bioabsorbable everolimus-eluting coronary stent system (ABSORB), expected to bring a revolutionary change in coronary artery disease (CAD) treatment; MicroPort's third-generation completely biodegradable drug-eluting stent Firehawk has completed clinical trials in China; Lepu Medical's completely biodegradable drug-eluting stent is also in active research and development.
China Interventional Cardiovascular Device Industry Report, 2013-2015 mainly covers the followings: Development, market demand, competition pattern, profit level, etc. of the industry;
Policy environment, impacts from upstream and downstream sectors, etc.;
Market size, supply and demand, product price, etc. of industry segments (including coronary stent, balloon catheter, guide wire, sheath group and auxiliary device), etc.;
Operation, interventional device cardiovascular business, operation in China, etc. of global companies (including Johnson & Johnson, Medtronic, Boston Scientific, Abbott Laboratories, B. Braun);
Operation, interventional cardiovascular device business, etc. of Chinese companies (including MicroPort, Lepu Medical, Lifetech Scientific, JW Medical, Liaoning Bio-medical Technology, OrbusNeich, SCW Medicath, Amtech Biotech and Starway Medical).
1. Overview of Interventional Cardiovascular Device Industry
1.2 Product Types and Applications
1.3 Industry Chain
2. Status Quo of China Interventional Cardiovascular Device Industry
2.1 Overview 2.2 Market Demand 2.3 Import and Export2.4 Competition Pattern2.5 Profit2.6 Entry Barriers2.6.1 Technology 2.6.2 Talent 2.6.3 Patent 2.6.4 Policy 2.6.5 Market Access
3. Development Environment for China Interventional Cardiovascular Device Industry
3.1 Policy Environment
3.1.1 Regulatory Policy
3.1.2 Industry Policy
3.2 Upstream and Downstream Sectors
4. Market Segments
4.1 Coronary Stent4.1.1 Market Profile4.1.2 Drug-Eluting Stent4.1.3 Bare Metal Stent4.1.4 Bioabsorbable Stent4.2 Balloon Catheter4.2.1 Market Profile4.2.2 Supply and Demand4.3 Catheter4.3.1 Market Profile4.3.2 Sales4.4 Guide Wire4.4.1 Market Profile4.4.2 Sales4.5 Sheath Group and Auxiliary Devices4.5.1 Market Profile4.5.2 Sales
5. Foreign Companies
5.1 Johnson & Johnson
5.1.3 Interventional Cardiovascular Device Business
5.1.4 Operation in China
5.2.3 Revenue Structure
5.2.4 Operation in China
5.3 Boston Scientific
5.3.3 Operation in China
5.4 Abbott Laboratories
5.4.3 Operation in China
5.5 B. Braun
5.5.3 Operation in China
6. Chinese Companies
6.1 MicroPort6.1.1 Profile6.1.2 Operation6.1.3 Revenue Structure6.1.4 Gross Margin6.1.5 R&D and Investment6.1.6 Interventional Cardiovascular Device Business6.1.7 Forecast and Outlook6.2 Lepu Medical6.2.1 Profile6.2.2 Operation6.2.3 Revenue Structure6.2.4 Gross Margin6.2.5 R&D and Investment6.2.6 Interventional Cardiovascular Device Business6.2.7 Forecast and Outlook6.3 Lifetech Scientific6.3.1 Profile6.3.2 Operation6.3.3 Revenue Structure6.3.4 Gross Margin6.3.5 R&D and Investment6.3.6 Interventional Cardiovascular Device Business6.4 JW Medical6.4.1 Profile6.4.2 Operation6.4.3 Development6.5 Liaoning Bio-medical6.5.1 Profile6.5.2 Operation6.5.3 Development6.6 OrbusNeich6.6.1 Profile6.6.2 Operation6.6.3 Development6.7 Sinomed6.7.1 Profile6.7.2 Operation6.7.3 Development6.8 SCW Medicath6.8.1 Profile6.8.2 Operation6.9 Amtech Biotech6.9.1 Profile6.9.2 Operation 6.10 Starway Medical
Johnson & JohnsonMedtronicBoston ScientificAbbott LaboratoriesB. BraunMicroPortLepu MedicalLifetech ScientificJW MedicalLiaoning Bio-medicalOrbusNeichSinomedSCW MedicathAmtech BiotechStarway MedicalTo order this report: China Interventional Cardiovascular Device Industry Report, 2013-2015 http://www.reportlinker.com/p0370585/China-Interventional-Cardiovascular-Device-Industry-Report-2013-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
Copyright©2012 PR Newswire.
All rights reserved